Header Logo

Connection

GAIL ECKHARDT to Half-Life

Back to Details
This is a "connection" page, showing publications GAIL ECKHARDT has written about Half-Life.
GAIL ECKHARDT
Connection Strength
0.025
Half-Life
  1. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):773-81.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.